Details of the Drug Combination

General Information of Drug Combination (ID: DC40DIQ)

Drug Combination Name
Tazarotene IDP-122
Indication
Disease Entry Status REF
Psoriasis Vulgaris Phase 4 [1]
Component Drugs Tazarotene   DM8SMD1 IDP-122   DM3A701
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tazarotene
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Psoriasis EA90 Approved [2]
Psoriasis vulgaris EA90 Approved [3]
Tazarotene Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor gamma (RARG) TT1Q3IE RARG_HUMAN Binder [6]
------------------------------------------------------------------------------------
Tazarotene Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Tazarotene Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Activity [8]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [9]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [10]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [9]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [11]
Sodium/iodide cotransporter (SLC5A5) OTU7E9G7 SC5A5_HUMAN Increases Expression [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)
Indication(s) of IDP-122
Disease Entry ICD 11 Status REF
Exanthem N.A. Approved [4]
Granuloma annulare N.A. Approved [4]
Primary cutaneous T-cell lymphoma N.A. Approved [4]
Plaque psoriasis EA90.0 Phase 3 [5]
IDP-122 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid hormone receptor ERR (ESRR) TTP3UTW ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN Agonist [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT06042647) Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
2 Tazarotene FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6952).
4 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31.
7 Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
8 Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J Cell Biochem. 2006 Feb 1;97(2):327-50. doi: 10.1002/jcb.20579.
9 [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]. Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug;25(8):972-4, 978.
10 Effects of ATRA, acitretin and tazarotene on growth and apoptosis of Tca8113 cells. J Huazhong Univ Sci Technolog Med Sci. 2005;25(4):393-6. doi: 10.1007/BF02828205.
11 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
12 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):797-826. doi: 10.1677/erc.1.01143.